塔泽梅托斯塔特的药理学和药理动力学
Marco Orleni1,2,3, Jan H Beumer4,5,6
1Cancer Therapeutics Program, UPMC Hillman Cancer Center, Room G27E, Hillman Research Pavilion, 5117 Centre Avenue, Pittsburgh, PA, 15213-1863, USA.
Cancer chemotherapy and pharmacology
|March 23, 2024
概括
塔泽米托斯塔特是一种新的FDA批准的EZH2抑制剂,用于特定的癌症. 它通过阻断EZH2,一个关键蛋白质,并显示了有前途的结果在临床试验中,先进的上皮质肉瘤和卵泡淋巴瘤.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
背景情况:
- 塔泽美托斯塔特是一种新型口服选择性抑制剂,是一种增强性黄体同源2 (EZH2) 的增强剂.
- 抑制EZH2是某些癌症的治疗策略,包括上皮状肉瘤和EZH2突变的卵泡淋巴瘤.
- 2020年FDA的批准是基于加速批准途径,利用2期试验的客观反应率和反应持续时间.
研究的目的:
- 审查tazemetostat的药理学,药理动力学和临床应用.
- 为了突出其作为一流EZH2抑制剂的作用机制.
- 讨论其已批准的指示和正在进行的组合疗法研究.
主要方法:
- 对tazemetostat的临床前和临床数据的审查.
- 分析其作用机制,与S-adenosylmethionine (SAM) 竞争,以抑制EZH2.2.
- 评估药物动力学特性,包括生物可用性,新陈代谢,分泌和药物相互作用.
主要成果:
- 塔泽米托斯塔特有效地降低了H3K27me3,这是EZH2抑制的药理学标志物.
- 它是口服生物可用,吸收快速,暴露与剂量成比例,不受食物或胃酸降低剂的影响.
- 通过CYP3A代谢,中枢神经系统透程度有限;对于脏或肝脏功能障碍,不需要调整剂量.
结论:
- 塔泽美托斯塔特是第一个批准用于癌症治疗的EZH2抑制剂.
- 它的药理动力学特征支持口服,并特别考虑药物相互作用 (例如,可纳).
- 目前正在进行的研究正在探索tazemetostat在各种恶性瘤的联合治疗中.
相关概念视频
Chronopharmacokinetics: Time-Dependent Pharmacokinetics
130
Chronopharmacokinetics studies the temporal change in drug absorption and elimination. These changes can be cyclical or non-cyclical. Cyclical changes occur over a regular interval, while non-cyclical changes occur over a longer, irregular period.
Time-dependent pharmacokinetics refers to non-cyclical changes in drug rate processes over a period of time. It can lead to nonlinear pharmacokinetics, where the relationship between drug concentration and time is not proportional. Non-cyclical...
Time-dependent pharmacokinetics refers to non-cyclical changes in drug rate processes over a period of time. It can lead to nonlinear pharmacokinetics, where the relationship between drug concentration and time is not proportional. Non-cyclical...
130
Tissue-Drug Binding: Localization of Drugs and its Significance
79
Body tissues, comprising approximately 40% of the body weight, are crucial in drug distribution and localization. These tissues can serve as drug storage sites, competing with plasma binding sites for drug molecules.
Drugs can bind to different tissue components, enhancing their distribution and localization. The factors influencing drug localization in tissues include the drug's lipophilicity, structural characteristics, tissue perfusion rate, and pH differences. These factors determine...
Drugs can bind to different tissue components, enhancing their distribution and localization. The factors influencing drug localization in tissues include the drug's lipophilicity, structural characteristics, tissue perfusion rate, and pH differences. These factors determine...
79
Pharmacokinetics: Overview
6.3K
Pharmacokinetics is a scientific discipline that focuses on the journey of a drug within the body, encompassing four key stages: absorption, distribution, metabolism, and elimination. The first stage, absorption, involves the drug's transfer into the bloodstream. Several factors dictate the extent and speed of this process. For example, the liver often metabolizes oral drugs before they reach systemic circulation, leading to only partial absorption. In contrast, intravenous (IV)...
6.3K
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
38
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
38
Drug Biotransformation: Overview
2.4K
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
2.4K
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
134
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
134
![Technical Aspect of the Automated Synthesis and Real-Time Kinetic Evaluation of [11C]SNAP-7941](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F59557.jpg&w=3840&q=50)

